A Compendium on Peripheral Arterial Disease
2015; Lippincott Williams & Wilkins; Volume: 116; Issue: 9 Linguagem: Inglês
10.1161/circresaha.115.306403
ISSN1524-4571
Autores Tópico(s)Muscle and Compartmental Disorders
ResumoHomeCirculation ResearchVol. 116, No. 9A Compendium on Peripheral Arterial Disease Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBA Compendium on Peripheral Arterial Disease John P. Cooke and Zhen Chen John P. CookeJohn P. Cooke From the Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX (J.P.C.); and Division of Cardiology, University of California San Diego (Z.C.). and Zhen ChenZhen Chen From the Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX (J.P.C.); and Division of Cardiology, University of California San Diego (Z.C.). Originally published24 Apr 2015https://doi.org/10.1161/CIRCRESAHA.115.306403Circulation Research. 2015;116:1505–1508The Broad Scope of Peripheral Arterial DiseasePeripheral arterial disease (PAD) is usually taken to mean arterial occlusive disease because of arteriosclerosis, impeding the blood flow to the lower extremity. Of course, it is important to keep in mind that a broader definition of PAD would include all noncoronary arterial disease, including carotid artery disease. Furthermore, there are many disorders that can cause arterial occlusive disease other than arteriosclerosis although it is by far the most common. These disorders can be due to pathobiology intrinsic to the vessel wall, as in vasculitis, thromboangiitis obliterans, or fibromuscular dysplasia; or secondary to extrinsic pathology as in compression syndromes, such as popliteal artery entrapment. Embolic disease (such as that due to atheroembolism from a diseased aorta, or cardiogenic thrombus) or dissection of the aorta, may cause occlusion of peripheral arteries. In addition, the broad scope of PADs includes nonocclusive arterial disease, such as aneurysms, traumatic or congenital arteriovenous fistulas or malformations, and vascular tumors. However, for the purposes of this compendium, we focus on atherosclerotic arterial occlusive disease that impairs blood flow to the lower extremities.Dying of NeglectDefined in this way, PAD is the most common disease that is most commonly overlooked. Although it is unusual for PAD to manifest in those aged 65 years, and ≈20% of individuals aged >80 years.1 Regrettably, most of these individuals are not diagnosed, as documented in the PARTNERS (PAD Awareness, Risk, and Treatment: New Resources for Survival) screening study.2 As a consequence, individuals with PAD are less likely than those with coronary artery disease to receive optimal medical therapy (OMT). This is a tragic situation because OMT saves life and limb. In their comprehensive and lucid review of medical therapy, Creager and Bonaca3 point out that the aims are 2-fold: to reduce cardiovascular morbidity and mortality, and to relieve symptoms and functional impairment associated with PAD. They detail how the use of statins, angiotensin-converting enzyme inhibitors, and antiplatelet agents substantially reduce cardiovascular morbidity and mortality in individuals with PAD. Furthermore, statins and angiotensin-converting enzyme inhibitors, as well as cilostazol, can improve walking distance. As discussed by several of the authors, supervised exercise has the greatest efficacy of medical therapies to improve walking distance. Tobacco cessation is a mainstay of treatment, as it improves functional capacity, prevents the progression of disease, and reduces the risk of bypass failure.3Given that there is effective medical therapy, why is PAD underdiagnosed and untreated? As noted by McDermott, most individuals with PAD do not have the classic symptomatology of intermittent claudication as defined by pain in the buttocks, thighs, or calves that occurs during walking, relieved by standing still.4 Only 10% to 30% of PAD patients manifest these symptoms. They may be sedentary, and not aware of their limitations, or the patients (and physicians) attribute the leg pain to musculoskeletal disease or neuropathy that often coexists in these elderly patients. Another cause of the poor recognition is suboptimal screening. It is not because screening procedures are highly technical or expensive. It is straightforward to make the diagnosis of PAD with simple equipment, that is, a blood pressure cuff and a hand-held Doppler. One measures the systolic pressure at the brachial, dorsalis pedis, and posterior tibial arteries. The ankle-brachial index (ABI) for each leg is calculated by taking the higher of the two pressures taken at the ankle, and dividing it by the higher of the 2 brachial pressures. The normal ABI is 1.0 to 1.2 (the systolic pressure at the ankle can be slightly higher than the systolic pressure measured at the brachial artery in a healthy individual because of pulse wave reflections). The diagnosis of PAD is made when the ABI≤0.9.The ABI is a useful screening approach that should be adopted in all medical practices that care for older adults. Indeed, the American Heart Association and American College of Cardiology have published guidelines recommending that individuals at risk have an ABI screening performed.5 Diabetics or smokers aged >55 years, and anyone aged >65 years, should have an ABI performed to detect undiagnosed PAD. The purpose of routine screening is not to identify patients for endovascular interventions. It is to identify individuals who are at greater risk for cardiovascular morbidity and mortality, so that they can get the proper medical treatment. Regrettably, the US Preventive Services Task Force has claimed that more evidence is required before ABI screening can be recommended. This assessment is delaying the widespread implementation of ABI screening, as well as the diagnosis and proper medical therapy for many US citizens.Risky BusinessCriqui and Aboyans2 are leading authorities on the epidemiology of PAD, and team up in this compendium to provide an elegant review of the risk factors determining the incidence and prevalence of PAD. Of course, the usual suspects play a role in atherosclerosis affecting the lower extremities, including tobacco, diabetes mellitus, age, dyslipidemia, and hypertension. However, in this regard, there are some curious differences between PAD and the other major arterial diseases, that is, the coronary and carotid vessels. Tobacco exposure is a risk factor for all 3, but seems to be a stronger determinant of PAD. This preferential effect on the limb vessels is unexplained, but 1 clue comes from the surprising observation that nicotine receptors are expressed by blood vessels.6 These nicotinic acetylcholine receptors mediate several vascular processes related to atherosclerosis, including neovascularization of atherosclerotic plaque and proliferation of vascular smooth muscle cells.7 The nicotinic receptors seem to be widespread in the vasculature, but is it possible that these receptors are differentially active in peripheral vessels? Of interest, Leeper and Khullo point out that 1 of the genetic variants that increases the risk of PAD is in a gene encoding a nicotinic acetylcholine receptor.8Diabetes mellitus is also a strong risk factor for PAD. Furthermore, patients with more severe disease (critical limb ischemia) are likely to be diabetic. Intriguingly, the arterial occlusive disease incurred by diabetic patients in their peripheral, as well as their coronary arteries tends to be more diffuse and with greater distal extent, by comparison to nondiabetics.2 In addition, diabetics often have more vascular calcification, sometimes extending to the digital arteries of the toes. The mechanisms underlying this propensity for distal and diffuse disease, with greater calcification, is not fully explained, but may be, in part, because of mesenchymal stem cells activated in the vessel wall by inflammatory and metabolic signals.Another unexplained finding is the increased risk of PAD in blacks, even after accounting for ethnic differences in the burden of risk factors.2 It is possible that unconventional risk factors, such as social stress or walkability of the urban environment could be involved. Other unconventional risk factors considered by Criqui and Aboyans2 include oral health or history of infectious disease, both of which are related to the intriguing new research front about the effects of the microbiome on the progression of atherosclerosis.Epidemiological studies that used questionnaires lack sensitivity as most patients with PAD do not have classical symptoms of intermittent claudication. Those epidemiological studies that use the ABI provide more accurate reflection of the incidence or prevalence of PAD. However, even the traditional ABI under reports PAD. Some lesions which may be hemodynamically significant during exercise, may not cause a pressure gradient at rest. Furthermore, the traditional method for expressing the ABI (ie, using the highest of the ankle pressures) may miss single vessel disease at the ankle. When the lowest of the ankle pressures is used, the number of patients classified as having PAD doubled in a large cohort of patients undergoing coronary angiography.9 On long-term follow up, the additional patients detected using this alternative ABI had greater mortality than those patients who were classified as not having PAD by either ABI method. Thus, the alternative ABI method identifies more patients that are at risk for cardiovascular mortality. Accordingly, there is reason to re-examine the methodology for the ABI calculation. An alternative approach for screening would be to develop a blood test for detecting patients with PAD.10 However, the current biomarkers currently do not have the sensitivity or specificity to replace the ABI measurement.Stepping ForwardHiatt et al11 have contributed greatly to our understanding of the pathobiology of PAD, and elucidate these mechanisms in this compendium. It is clear from their work and the studies of McDermott4 that the functional limitation of patients with PAD is multifactorial. Although the impaired perfusion may be primary, secondary changes in the skeletal muscle, including mitochondrial dysfunction, denervation, and replacement of myocytes with fibrofatty tissue contribute. Other concomitant conditions that may exacerbate the vascular impairment and functional limitations include oxidative stress, inflammation, endothelial vasodilator dysfunction, increased blood viscosity, and hypercoagulation. The contribution of these other mechanisms may explain why limb hemodynamics are not predictive of the patient's performance on a treadmill test.12 Attention to other mechanism that impair functional capacity could lead to new therapeutic avenues. In the meantime, given its established efficacy to improve walking distance, the authors recommend supervised exercise training. Exercise has beneficial effects on the lipoprotein profile, resting blood pressure and heart rate, insulin sensitivity, neurohormonal activity, and endothelial elaboration of vasoprotective factors.13 Although exercise training is effective at improving functional capacity, it is not known if an exercise training program can reduce mortality in patients with PAD. However, it is noteworthy that in patients with PAD, functional capacity is a stronger predictor of mortality than are the classical risk factors.14 Finally, it is worth noting that many patients with PAD tend to be sedentary individuals. Whether this is cause or effect has recently been addressed by a study revealing that recalled lifetime recreational activity is positively correlated to ABI.15 Thus, it seems that a lifetime of sedentary behavior increases the risk for PAD.Nature Versus NurtureOf course, there must be genetic factors that contribute to the risk of developing PAD. However, the search for genetic determinants has not been as successful for PAD as it has for coronary artery disease. Given the heterogeneity of PAD and the strong environmental influences Kullo and Leeper8 suggest approaches that may yield more insights into hereditary mechanisms of disease. Large collaborative meta-analyses from genome-wide association studies are ongoing. Another approach is to use large DNA repositories tied to electronic medical records. Also, it will be useful to study more homogenous subsets of individuals with PAD, stratified by risk factors and location of disease. In addition, novel insights might be gained by studying arterial diseases that have stronger genetic determinants and which share some biological processes with atherosclerosis (such as the abnormal proliferation of vascular smooth muscle cells in fibromuscular dysplasia and in atherosclerosis). In addition, in families with a strong predisposition to PAD, whole genome/exome sequencing has uncovered new candidates, such as variants of NT5E (involved in adenosine metabolism) and IN080D (involved in chromatin remodeling). The authors propose that because it is difficult to obtain vascular tissue, one might perform RNA-sequencing studies of circulating cells that might report on inflammatory or coagulation processes that may contribute to PAD. However, such indirect assessments may be surpassed with the new technology of induced pluripotency. For example, one may harvest easily accessed tissue from patients, for example, skin fibroblasts, and generated from these cells induced pluripotent stem cells (iPSCs) using the Yamanaka approach. Subsequently, the iPSCs can be differentiated into cells that are less easily obtained from the patient, such as endothelial cells.16 These iPSC-derived cells permit the study of disease-in-a-dish and are accelerating our discovery of new pathobiological insights and therapeutic approaches.17Finally, the authors link nature and nurture by discussing the role of epigenetics in vascular disease. Epigenetics is the study of factors that can alter gene expression by modifying DNA, altering the chromatin structure that is physically associated with DNA, or modulating the RNA transcripts of the DNA. Noncoding RNAs such as microRNAs, regulate multiple vascular functions. For example, microRNA-92a has been characterized as an important modulator of angiogenesis, nitric oxide-dependent vasodilation, and endothelial innate immune response and inflammation.18,19 Powerful new techniques, such as ChIP-Seq are permitting rapid profiling of chromatin modifications that influence gene activity. Using such techniques, environmental factors such as tobacco have been found to alter the epigenetic state.8 Relevant to this discussion is the recent observation that inflammatory signaling has global effects on chromatin structure, which can increase the open probability state of the epigenome.20 In this state, cells have greater epigenetic plasticity and as a consequence, greater phenotypic fluidity. Indeed, the generation of iPSCs from somatic cells requires activation of inflammatory signaling. Furthermore, in this state of epigenetic plasticity, somatic cells have the capacity to transdifferentiate into other somatic cells.21 This phenomenon of transflammation may underlie pathological processes involved in atherosclerosis, such as endothelial-to-mesenchyme transition, but it may also be therapeutically modulated.Vascular RegenerationThe ability to generate iPSC-derived vascular cells might open a new chapter in stem cell and angiogenic therapies for vascular disease.22 To be sure, this field needs new approaches as the early promise of these regenerative therapies has not been met. Cooke and Losordo23 provide an overview of the scientific foundation for PAD regenerative therapy, and the clinical results to date. Although it is clear from the preclinical studies that angiogenesis and arteriogenesis can be manipulated by a variety of cytokines and progenitor cells, something has been lost in the translation to clinical studies. Although some phase I and II studies of these regenerative therapies have been encouraging, the definitive phase III studies have been negative. This may be because of deficiencies in the commonly used murine hindlimb ischemia model. In this model, the limb ischemia is surgically induced, and is really a model of acute ischemia. The authors suggest that results may be more predictive if an animal model of chronic arterial occlusive disease in the setting of cardiovascular risk factors was used. Such a model might also be more useful in addressing unanswered questions related to the dose, duration of treatment, and delivery method to be used. Although a successful phase III study is yet to be reported, there is a phase III study underway of plasmid DNA encoding hepatocyte growth factor for intramuscular injection, as well as phase II studies of a variety of progenitor cells for PAD.23When to InterveneWhen should the patient with PAD have surgery or endovascular intervention? Clearly, when a patient suffers from critical limb ischemia (with pain in the foot at rest, a nonhealing leg ulcer, or gangrene), or in the setting of an acutely ischemic limb, an interventional approach must be considered. However, the answer is less clear for the patient with intermittent claudication. The question is addressed from different perspectives by several authors in the compendium. Creager and Bonaca3 describe the trials that have compared the symptomatic and functional benefits of medical therapy versus endovascular approaches. The CLEVER (Claudication: Exercise Vs. Endoluminal Revascularization) study examined the benefits of OMT, OMT+exercise training, and OMT+endovascular stenting in patients with aorto-iliac disease. In brief, OMT+exercise training was superior for the primary end point of walking distance on a treadmill, whereas the secondary end point of quality of life was somewhat better for OMT+endovascular stenting. In the ERASE (Endovascular Revascularization and Supervised Exercise) trial, patients with intermittent claudication because of aorto-iliac or superficial femoral artery disease were treated with supervised exercise training±endovascular stenting. Those patients who were also stented had a significantly better result (in walking distance and quality of life) that was sustained to 12 months. Thus, selected patients with intermittent claudication, not responding sufficiently to medical therapy, may benefit from a more interventional approach, combined with OMT.In those patients requiring a more invasive approach, the endovascular approach is often preferred over surgery because of the decreased morbidity of most endovascular procedures by comparison to open procedures. Kinlay and Thukkani24 provide a thoughtful discussion of the decision process and approaches required for endovascular treatment, which is nicely complemented by the analysis of the surgical approach by Conte and Vartanian.25Together, these articles illustrate the complexity of these decisions, which require a comprehensive assessment of the patient's current medical regiment, their functional status, the anatomic pattern of disease, and the comorbid conditions. A variety of preprocedural imaging methods and physiological tests can provide valuable information that modifies the approach. In general, patients with focal and discrete lesions, particularly when the disease is more proximal (ilio-femoral), respond well to endovascular intervention. When the anatomic disease is more advanced patterns (eg, extensive and diffuse lesions, long chronic total occlusions, or concomitant aneurysms), a surgical approach is generally preferred. In some complex patients, a hybrid approach, combining catheter-based and open techniques, is preferred. That being said, the domain of endovascular intervention continues to expand with the advent of new technology that improves endovascular results, such as drug-eluting or covered stents, and drug-eluting balloons. Whatever the intervention, postprocedural pharmacotherapy is needed to minimize failure of the procedure (eg, thrombosis). Once the patient leaves the hospital, what should be the intensity and method of surveillance to detect and correct early recurrence of disease before the conduit becomes occluded? These and other topics are cogently discussed. Although the field of vascular intervention has radically changed in the past few decades, the pace of change is likely to continue with the adoption of such exciting new technologies as three-dimensional imaging with robotic manipulation of endovascular devices, and with the development of tissue-engineered vascular grafts.To conclude, much is afoot in the world of PAD. We appreciate the opportunity to bring attention to a disease that is too often overlooked. The good news is that there are robust methods to detect the disease, to fully characterize the severity of the disease by imaging and functional testing, to substantially alleviate symptoms and improve functional capacity, and to prevent death and disability. We thank our coauthors for their commitment to this work and to the field of vascular medicine, and we hope that the readers enjoy our Compendium.Sources of FundingThis work was supported, in part, by National Institutes of Health funding to Dr Cooke (U01 HL100397, U01 HL099997, 1UM1 HL113456, and 1R01 EY02060901) and to Z. Chen (K99HL122368).DisclosuresNone.FootnotesCorrespondence to John P. Cooke, MD, Department of Cardiovascular Sciences, Houston Methodist Research Institute, 6670 Bertner Ave, Mail Stop: R10-S, Houston, TX 77030. E-mail [email protected]References1. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR.Peripheral arterial disease detection, awareness, and treatment in primary care.JAMA. 2001; 286:1317–1324.CrossrefMedlineGoogle Scholar2. Criqui MH, Aboyans V.Epidemiology of peripheral artery disease.Circ Res. 2015; 116:1509–1526. doi: 10.1161/CIRCRESAHA.116.303849.Google Scholar3. Bonaca MP, Creager MA.Pharmacological treatment and current management of peripheral artery disease.Circ Res. 2015; 116:1579–1598. doi: 10.1161/CIRCRESAHA.114.303505.Google Scholar4. McDermott MM.Lower extremity manifestations of peripheral artery disease: the pathophysiologic and functional implications of leg ischemia.Circ Res. 2015; 116:1540–1550. doi: 10.1161/CIRCRESAHA.114.303517.Google Scholar5. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss L, Golzarian J, Gornik HL, Jaff MR, Moneta GL, Olin JW, Stanley JC, White CJ, White JV, Zierler RE; American College of Cardiology Foundation Task Force; American Heart Association Task Force. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol. 2013 61(14):1555–1570. doi: 10.1016/j.jacc.2013.01.004.CrossrefMedlineGoogle Scholar6. Heeschen C, Jang J, Hoai-Ky V, Kaji S, Yang P, Hu RS, Cooke JP.Nicotine is an agent of angiogenesis. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis.Nat Med2001; 7(7):833–839. doi: 10.1038/89961.CrossrefMedlineGoogle Scholar7. Lee J, Cooke JP.The role of nicotine in the pathogenesis of atherosclerosis.Atherosclerosis2011; 215(2):281–283. doi: 10.1016/j.atherosclerosis.2011.01.003.CrossrefMedlineGoogle Scholar8. Kullo IJ, Leeper NJ.The genetic basis of peripheral arterial disease: current knowledge, challenges, and future directions.Circ Res. 2015; 116:1551–1560. doi: 10.1161/CIRCRESAHA.116.303518.Google Scholar9. Nead KT, Cooke JP, Olin JW, Leeper NJ.Alternative ankle-brachial index method identifies additional at-risk individuals.J Am Coll Cardiol. 2013; 62(6):553–559. doi: 10.1016/j.jacc.2013.04.061.CrossrefMedlineGoogle Scholar10. Wilson AM, Cooke JP.Biomarkers in peripheral arterial disease.J Am Coll Cardiol. 2010; 55(19):2017–2023.CrossrefMedlineGoogle Scholar11. Hiatt WR, Armstrong EJ, Larson CJ, Brass EP.Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease.Circ Res. 2015; 116:1527–1539. doi: 10.1161/CIRCRESAHA.116.303566.Google Scholar12. Szuba A, Oka RK, Harada R, Cooke JP.Limb hemodynamics are not predictive of functional capacity in patients with PAD.Vasc Med. 2006; 11(3):155–163.CrossrefMedlineGoogle Scholar13. Chiu JJ, Chien S.Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives.Physiol Rev. 2011; 91(1):327–387. doi: 10.1152/physrev.00047.2009.CrossrefMedlineGoogle Scholar14. Leeper NJ, Myers J, Zhou M, Nead KT, Syed A, Kojima Y, Caceres RD, Cooke JP.Exercise capacity is the strongest predictor of mortality in patients with peripheral arterial disease.J Vasc Surg. 2013; 57(3):728–733. doi: 10.1016/j.jvs.2012.07.051.CrossrefMedlineGoogle Scholar15. Wilson AM, Sadrzadeh-Rafie AH, Myers J, Assimes T, Nead KT, Higgins M, Gabriel A, Olin J, Cooke JP.Low lifetime recreational activity is a risk factor for peripheral arterial disease.J Vasc Surg. 2011; 54(2):427–432. doi: 10.1016/j.jvs.2011.02.052.CrossrefMedlineGoogle Scholar16. Rufaihah AJ, Huang NF, Jame S, Lee J, Nguyen HN, Byers B, De A, Okogbaa JN, Rollins M, Reijo-Pera R, Gambhir SS, Cooke JP.Endothelial cells derived from human IPSCs increase capillary density and improve perfusion in a mouse model of peripheral arterial disease.Arterioscler Thromb Vasc Biol. 2011; 31(11):e72–e79. doi: 10.1161/ATVBAHA.111.230938.LinkGoogle Scholar17. Volz KS, Miljan E, Khoo A, Cooke JP.Development of pluripotent stem cells for vascular therapy.Vascul Pharmacol. 2012; 56(5–6):288–296. doi: 10.1016/j.vph.2012.02.010.CrossrefMedlineGoogle Scholar18. Chen Z, Wen L, Martin M, et al. Oxidative stress activates endothelial innate immunity via sterol regulatory element binding protein 2 (SREBP2) transactivation of MicroRNA-92a.circulation.2015; 131(9):805–814. doi: 10.1161/CIRCULATIONAHA.114.013675.Google Scholar19. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice.Science. 2009; 324:1710–1713. doi: 10.1126/science.1174381.CrossrefMedlineGoogle Scholar20. Lee J, Sayed N, Hunter A, Au KF, Wong WH, Mocarski E, Reijo Pera R, Cooke JP.Activation of innate immunity is required for efficient nuclear reprogramming.Cell. 2012; 151(3):547–558. doi: 10.1016/j.cell.2012.09.034.CrossrefMedlineGoogle Scholar21. Sayed N, Wong WT, Ospino F, Meng S, Lee J, Jha A, Dexheimer P, Aronow BJ, Cooke JP.Transdifferentiation of human fibroblasts to endothelial cells: role of innate immunity.Circulation. 2015; 131(3):300–309. doi: 10.1161/CIRCULATIONAHA.113.007394.LinkGoogle Scholar22. Leeper NJ, Hunter AL, Cooke JP.Stem cell therapy for vascular regeneration: adult, embryonic, and induced pluripotent stem cells.Circulation. 2010; 122:517–526. doi: 10.1161/CIRCULATIONAHA.109.881441.LinkGoogle Scholar23. Cooke JP, Losordo DW.Modulating the vascular response to limb ischemia: angiogenic and cell therapies.Circ Res. 2015; 116:1561–1578. doi: 10.1161/CIRCRESAHA.115.303565.Google Scholar24. Thukkani A, Kinlay S.Endovascular intervention for peripheral artery disease.Circ Res. 2015; 116:1599–1613. doi: 10.1161/CIRCRESAHA.116.303503.Google Scholar25. Vartanian SM, Conte MS.Surgical intervention for peripheral artery disease.Circ Res. 2015; 116:1614–1628. doi: 10.1161/CIRCRESAHA.116.303504.Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Yang Q, Li C and Chen Q (2022) SS31 Ameliorates Oxidative Stress via the Restoration of Autophagic Flux to Protect Aged Mice From Hind Limb Ischemia, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2022.789331, 9 Deppen J, Ginn S, Kim N, Wang L, Voll R, Liang S, Goodman M, Oshinski J and Levit R (2021) A Swine Hind Limb Ischemia Model Useful for Testing Peripheral Artery Disease Therapeutics, Journal of Cardiovascular Translational Research, 10.1007/s12265-021-10134-8, 14:6, (1186-1197), Online publication date: 1-Dec-2021. Galvão N, Bandeira M, Oliveira de Carvalho E, Woo K, Nogueira P and Conceição de Gouveia Santos V (2021) Prevalence of diabetic foot ulcers and their associated factors in patients from public hospitals in manaus-am, Journal of Tissue Viability, 10.1016/j.jtv.2021.07.006, 30:4, (612-615), Online publication date: 1-Nov-2021. Flores A, Demsas F, Leeper N and Ross E (2021) Leveraging Machine Learning and Artificial Intelligence to Improve Peripheral Artery Disease Detection, Treatment, and Outcomes, Circulation Research, 128:12, (1833-1850), Online publication date: 11-Jun-2021. Shimotsu R, Hotta K, Ikegami R, Asamura T, Tabuchi A, Masamoto K, Yagishita K, Poole D and Kano Y (2021) Vascular permeability of skeletal muscle microvessels in rat arterial ligation model: in vivo analysis using two-photon laser scanning microscopy, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 10.1152/ajpregu.00135.2020, 320:6, (R972-R983), Online publication date: 1-Jun-2021. Izzo M, Carrizzo A, Izzo C, Cappello E, Cecere D, Ciccarelli M, Iannece P, Damato A, Vecchione C and Pompeo F (2021) Vitamin D: Not Just Bone Metabolism but a Key Player in Cardiovascular Diseases, Life, 10.3390/life11050452, 11:5, (452) Meng S, Lv J, Chanda P, Owusu I, Chen K and Cooke J (2020) Reservoir of Fibroblasts Promotes Recovery From Limb Ischemia, Circulation, 142:17, (1647-1662), Online publication date: 27-Oct-2020. Krishna S (2019) Vitamin D as A Protector of Arterial Health: Potential Role in Peripheral Arterial Disease Formation, International Journal of Molecular Sciences, 10.3390/ijms20194907, 20:19, (4907) Petrak K, Vissapragada R, Shi S, Siddiqui Z, Kim K, Sarkar B and Kumar V (2019) Challenges in Translating from Bench to Bed-Side: Pro-Angiogenic Peptides for Ischemia Treatment, Molecules, 10.3390/molecules24071219, 24:7, (1219) Murrow J, Brizendine J, Djire B, Young H, Rathbun S, Nilsson K and McCully K (2018) Near infrared spectroscopy-guided exercise training for claudication in peripheral arterial disease, European Journal of Preventive Cardiology, 10.1177/2047487318795192, 26:5, (471-480), Online publication date: 1-Mar-2019. Abaraogu U, Ezenwankwo E, Dall P, Seenan C and Andras A (2018) Living a burdensome and demanding life: A qualitative systematic review of the patients experiences of peripheral arterial disease, PLOS ONE, 10.1371/journal.pone.0207456, 13:11, (e0207456) Watanabe A, Poole D and Kano Y (2017) The effects of RSR13 on microvascular P o 2 kinetics and muscle contractile performance in the rat arterial ligation model of peripheral arterial disease , Journal of Applied Physiology, 10.1152/japplphysiol.00257.2017, 123:4, (764-772), Online publication date: 1-Oct-2017. Vart P, Coresh J, Kwak L, Ballew S, Heiss G and Matsushita K (2017) Socioeconomic Status and Incidence of Hospitalization With Lower‐Extremity Peripheral Artery Disease: Atherosclerosis Risk in Communities Study, Journal of the American Heart Association, 6:8, Online publication date: 2-Aug-2017.Rigato M, Monami M and Fadini G (2017) Autologous Cell Therapy for Peripheral Arterial Disease, Circulation Research, 120:8, (1326-1340), Online publication date: 14-Apr-2017. ATALAY Ö, SEVİM H, KARAHİSAR TURAN S, A. ONUR M and A. GÜRPINAR Ö (2017) The effects of mesenchymal stem cells on the structure and contractile force of the carotid artery in a rat aneurysm model, TURKISH JOURNAL OF MEDICAL SCIENCES, 10.3906/sag-1701-183, 47, (1634-1641), . Smadja D and Silvestre J (2016) Stem-Cell-Based Therapies for Vascular Regeneration in Peripheral Artery Diseases Stem Cells in Toxicology and Medicine, 10.1002/9781119135449.ch17, (324-346) Sigvant B, Kragsterman B, Falkenberg M, Hasvold P, Johansson S, Thuresson M and Nordanstig J (2016) Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization, Journal of Vascular Surgery, 10.1016/j.jvs.2016.03.429, 64:4, (1009-1017.e3), Online publication date: 1-Oct-2016. de Vries M, Simons K, Jukema J, Braun J and Quax P (2016) Vein graft failure: from pathophysiology to clinical outcomes, Nature Reviews Cardiology, 10.1038/nrcardio.2016.76, 13:8, (451-470), Online publication date: 1-Aug-2016. Kumar V, Liu Q, Wickremasinghe N, Shi S, Cornwright T, Deng Y, Azares A, Moore A, Acevedo-Jake A, Agudo N, Pan S, Woodside D, Vanderslice P, Willerson J, Dixon R and Hartgerink J (2016) Treatment of hind limb ischemia using angiogenic peptide nanofibers, Biomaterials, 10.1016/j.biomaterials.2016.04.032, 98, (113-119), Online publication date: 1-Aug-2016. Gommans L, Hageman D, Jansen I, de Gee R, van Lummel R, Verhofstad N, Scheltinga M and Teijink J (2016) Minimal correlation between physical exercise capacity and daily activity in patients with intermittent claudication, Journal of Vascular Surgery, 10.1016/j.jvs.2015.10.060, 63:4, (983-989), Online publication date: 1-Apr-2016. April 24, 2015Vol 116, Issue 9 Advertisement Article InformationMetrics © 2015 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.115.306403PMID: 25908724 Originally publishedApril 24, 2015 Keywordsintermittent claudicationcritical limb ischemiaEditorialsarteryPDF download Advertisement
Referência(s)